PDS Biotechnology (PDSB)
Market Price (3/19/2026): $0.6496 | Market Cap: $30.4 MilSector: Health Care | Industry: Biotechnology
PDS Biotechnology (PDSB)
Market Price (3/19/2026): $0.6496Market Cap: $30.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -162% | Penny stockMkt Price is 0.6 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 | |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -119% | ||
| Key risksPDSB key risks include [1] potential failure or delay of the pivotal Phase 3 VERSATILE-003 trial, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -162% |
| Penny stockMkt Price is 0.6 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -119% |
| Key risksPDSB key risks include [1] potential failure or delay of the pivotal Phase 3 VERSATILE-003 trial, Show more. |
Qualitative Assessment
AI Analysis | Feedback
PDS Biotechnology (PDSB) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Analyst downgrade and reiterated "Sell" rating contributed to negative sentiment.
B. Riley Securities lowered its price target for PDS Biotechnology from $5 to $3 on November 25, 2025, shortly before the specified period, signaling a more cautious outlook. Further impacting sentiment, Weiss Ratings reiterated a "Sell (E+)" rating for PDSB on January 22, 2026. By March 2026, the consensus among Wall Street analysts shifted to a "Hold" rating for the stock.
2. Market "digestion" or "sell the news" reaction to clinical advancements.
Despite a series of positive clinical and patent-related updates, the stock experienced a decline. PDS Biotech announced FDA alignment on using Progression-Free Survival (PFS) as a primary endpoint for its Phase 3 VERSATILE-003 trial in January 2026, with the protocol formally adopted in February 2026, potentially enabling an accelerated approval pathway for PDS0101. Additionally, preliminary positive Phase 2 results for PDS01ADC in prostate cancer were presented in late January 2026, reporting a median progression-free survival of 9.6 months. The stock's negative trend suggests that these positive developments may have been largely anticipated or led to profit-taking by investors.
Show more
1. Analyst downgrade and reiterated "Sell" rating contributed to negative sentiment.
B. Riley Securities lowered its price target for PDS Biotechnology from $5 to $3 on November 25, 2025, shortly before the specified period, signaling a more cautious outlook. Further impacting sentiment, Weiss Ratings reiterated a "Sell (E+)" rating for PDSB on January 22, 2026. By March 2026, the consensus among Wall Street analysts shifted to a "Hold" rating for the stock.
2. Market "digestion" or "sell the news" reaction to clinical advancements.
Despite a series of positive clinical and patent-related updates, the stock experienced a decline. PDS Biotech announced FDA alignment on using Progression-Free Survival (PFS) as a primary endpoint for its Phase 3 VERSATILE-003 trial in January 2026, with the protocol formally adopted in February 2026, potentially enabling an accelerated approval pathway for PDS0101. Additionally, preliminary positive Phase 2 results for PDS01ADC in prostate cancer were presented in late January 2026, reporting a median progression-free survival of 9.6 months. The stock's negative trend suggests that these positive developments may have been largely anticipated or led to profit-taking by investors.
Show more
Stock Movement Drivers
Fundamental Drivers
The -15.7% change in PDSB stock from 11/30/2025 to 3/18/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3182026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.77 | 0.65 | -15.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 47 | 47 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/18/2026| Return | Correlation | |
|---|---|---|
| PDSB | -15.7% | |
| Market (SPY) | -3.2% | 37.7% |
| Sector (XLV) | -6.7% | 5.8% |
Fundamental Drivers
The -47.6% change in PDSB stock from 8/31/2025 to 3/18/2026 was primarily driven by a -2.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3182026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.24 | 0.65 | -47.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 46 | 47 | -2.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/18/2026| Return | Correlation | |
|---|---|---|
| PDSB | -47.6% | |
| Market (SPY) | 2.8% | 37.2% |
| Sector (XLV) | 7.6% | 6.8% |
Fundamental Drivers
The -51.2% change in PDSB stock from 2/28/2025 to 3/18/2026 was primarily driven by a -21.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3182026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.33 | 0.65 | -51.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 37 | 47 | -21.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/18/2026| Return | Correlation | |
|---|---|---|
| PDSB | -51.2% | |
| Market (SPY) | 12.3% | 34.5% |
| Sector (XLV) | 0.1% | 25.3% |
Fundamental Drivers
The -91.5% change in PDSB stock from 2/28/2023 to 3/18/2026 was primarily driven by a -39.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3182026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.65 | 0.65 | -91.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 28 | 47 | -39.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/18/2026| Return | Correlation | |
|---|---|---|
| PDSB | -91.5% | |
| Market (SPY) | 73.1% | 34.8% |
| Sector (XLV) | 21.1% | 22.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PDSB Return | 279% | 63% | -62% | -67% | -53% | -10% | -68% |
| Peers Return | 14% | -18% | -17% | -25% | -10% | 30% | -32% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -2% | 79% |
Monthly Win Rates [3] | |||||||
| PDSB Win Rate | 58% | 50% | 33% | 33% | 25% | 67% | |
| Peers Win Rate | 48% | 42% | 37% | 40% | 50% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| PDSB Max Drawdown | 0% | -63% | -70% | -67% | -56% | -18% | |
| Peers Max Drawdown | -24% | -44% | -41% | -35% | -36% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IOVA, INO, MRK, GILD, MRNA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/18/2026 (YTD)
How Low Can It Go
| Event | PDSB | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -82.6% | -25.4% |
| % Gain to Breakeven | 475.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -78.6% | -33.9% |
| % Gain to Breakeven | 368.2% | 51.3% |
| Time to Breakeven | 109 days | 148 days |
| 2018 Correction | ||
| % Loss | -99.4% | -19.8% |
| % Gain to Breakeven | 16698.1% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to IOVA, INO, MRK, GILD, MRNA
In The Past
PDS Biotechnology's stock fell -82.6% during the 2022 Inflation Shock from a high on 9/23/2021. A -82.6% loss requires a 475.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About PDS Biotechnology (PDSB)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
AI Analysis | Feedback
Here are 1-3 brief analogies for PDS Biotechnology (PDSB):
- Think of them as a clinical-stage Moderna, but with a primary focus on using the immune system to fight cancer, alongside vaccine development.
- Like a smaller, emerging Bristol Myers Squibb (BMS) dedicated to developing innovative immune-based treatments for cancer and infectious diseases.
AI Analysis | Feedback
- PDS0101 (HPV16): A lead clinical-stage cancer immunotherapy for recurrent/metastatic head and neck cancer, HPV-associated malignancies, and cervical cancer.
- PDS0102 (TARP): A preclinical cancer immunotherapy candidate targeting prostate and breast cancers.
- PDS0103 (MUC-1): A preclinical cancer immunotherapy candidate for ovarian, colorectal, lung, and breast cancers.
- PDS0104 (Tyrosinase-related protein 2): A preclinical candidate for the treatment of melanoma.
- PDS0201: A preclinical candidate for treating tuberculosis.
- PDS0202: A preclinical influenza vaccine candidate.
- PDS0203: A preclinical vaccine candidate for the prevention of COVID-19.
AI Analysis | Feedback
PDS Biotechnology (PDSB) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines. As such, its product candidates are currently in various stages of clinical trials or preclinical development and are not yet commercially available.
Therefore, PDS Biotechnology does not currently have major customers that purchase its products, as its therapies have not received regulatory approval for commercial sale to individuals (patients) or other companies (e.g., hospitals, pharmacies, or distributors).
The company does engage in strategic "license and collaboration agreements" with entities such as the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. These relationships are critical for funding, research, development, and potential future commercialization, but these entities are partners and licensees rather than direct customers of commercial products.
AI Analysis | Feedback
- Lonza Group AG (LONN)
AI Analysis | Feedback
Frank Bedu-Addo, President and Chief Executive Officer
Frank Bedu-Addo is a co-founder of PDS Biotechnology, established in 2005, and has served as its President and CEO since its inception. He is recognized as a life science entrepreneur and executive with a track record of successfully starting and growing biotechnology organizations. Prior to PDS Biotechnology, Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc., where he managed all business and drug development operations. He also successfully established and managed Cardinal Health's East Coast biotechnology drug development operations. His earlier career included contributing to drug development in various roles at Akzo-Nobel, Elan (The Liposome Co.), and Schering-Plough. He holds an M.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Pittsburgh.
Lars Boesgaard, Chief Financial Officer
Lars Boesgaard serves as the Chief Financial Officer for PDS Biotechnology. His background information regarding founding or managing other companies, selling companies, or a pattern of private equity backing is not readily available in the provided search results.
Gregory Conn, Chief Scientific Officer
Gregory Conn is the Chief Scientific Officer at PDS Biotechnology. His specific background details were not found in the provided search results.
Kirk Shepard, Chief Medical Officer
Kirk Shepard serves as the Chief Medical Officer at PDS Biotechnology. He oversees all clinical development programs for the company's Versamune® platform. Dr. Shepard is a recognized authority in clinical oncology and immunotherapy, having led the clinical development of multiple oncology drugs and immunotherapies over two decades. Previously, he was the global lead for several cancer trials at AstraZeneca and served as Chief Medical Officer at Callisto Pharmaceuticals and Cornerstone Pharmaceuticals. He was also a Medical Officer at the FDA's CBER Division, Oncology Branch, where he was involved in the medical review of Avastin® and Erbitux®. Dr. Shepard holds an M.D. from Duke University and completed his fellowship training in hematology and oncology at Tufts-New England Medical Center and the Dana-Farber Cancer Center.
Stephan Toutain, Chief Operating Officer
Stephan Toutain is the Chief Operating Officer at PDS Biotechnology. His specific background details were not found in the provided search results.
AI Analysis | Feedback
- Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, PDS Biotechnology's future success is critically dependent on the successful completion of clinical trials for its product candidates, particularly PDS0101, which is in Phase II. Failure to demonstrate safety and efficacy in clinical trials, or significant delays in these trials, could prevent the company from obtaining necessary regulatory approvals and subsequently commercializing its products.
- Funding and Capital Requirements Risk: The development of biopharmaceutical products through clinical trials is an expensive and lengthy process. PDS Biotechnology will require substantial additional funding to continue its research, development, and clinical activities. There is a significant risk that the company may not be able to raise sufficient capital on favorable terms, or at all, which could severely impact its ability to advance its pipeline or continue operations.
- Intellectual Property Protection and Competition Risk: PDS Biotechnology's competitive position relies on its ability to obtain, maintain, and protect its intellectual property rights for its product candidates. The biopharmaceutical industry is highly competitive, and the company's products, even if successful, may face intense competition from existing therapies or new treatments developed by larger, more established pharmaceutical companies. Challenges to its patents or the inability to secure robust intellectual property protection could significantly harm its business prospects.
AI Analysis | Feedback
The established and highly competitive market for COVID-19 vaccines, dominated by numerous approved and widely distributed products, poses a significant emerging threat to the commercial viability of PDS Biotechnology's preclinical COVID-19 vaccine candidate (PDS0203).AI Analysis | Feedback
PDS Biotechnology (PDSB) develops multifunctional cancer immunotherapies and vaccines. The addressable markets for its main products and services are as follows:
- PDS0101 (HPV16) for Human Papillomavirus (HPV) associated malignancies (including cervical, oropharyngeal, and anal cancers) and recurrent/metastatic head and neck cancer: The company has stated that there are multi-billion-dollar estimated U.S. market opportunities across HPV16-positive indications, prostate, and colorectal cancer indications. Over 630,000 cases of HPV-associated malignancies, including cervical, oropharyngeal, and anal cancer, occur worldwide annually.
- For cervical cancer, the global treatment market size was valued at USD 6.9 billion in 2022 and is projected to reach USD 11.5 billion by 2032.
- For head and neck cancer, the global market size was estimated at USD 2.3 billion in 2022 and is expected to reach USD 4.9 billion by 2032.
- PDS0102 (TARP) for prostate and breast cancers:
- The global prostate cancer therapeutics market size was estimated at USD 17.0 billion in 2024 and is projected to reach USD 31.99 billion by 2030. In the 7MM (United States, EU4, United Kingdom, and Japan), the prostate cancer treatment market size was nearly USD 12,300 million in 2023.
- The global breast cancer drugs market size was estimated at USD 36.62 billion in 2024 and is projected to reach USD 69.72 billion by 2033. The U.S. breast cancer market is projected to reach over USD 11.55 billion by 2034, increasing from USD 7.71 billion in 2025.
- PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers:
- The global ovarian cancer market size was estimated to be USD 3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. The U.S. ovarian cancer drugs market size is evaluated at USD 1.30 billion in 2025 and is projected to be worth around USD 2.57 billion by 2035.
- The global colorectal cancer therapeutics market size was estimated at USD 12.79 billion in 2024 and is projected to reach USD 19.95 billion by 2034. In 2023, the United States held the largest Colorectal Cancer Market Share among the 7MM, accounting for approximately 40% of the total market.
- The global lung cancer market size was estimated at USD 35.1 billion in 2024 and is expected to grow to USD 95.1 billion in 2034. The U.S. market for lung cancer was valued at USD 15.4 billion in 2024.
- PDS0104 for melanoma: The global melanoma therapeutics market size was estimated at USD 5.83 billion in 2024 and is estimated to reach USD 10.26 billion by 2030. The melanoma market in the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 4.2 Billion in 2024 and is expected to reach USD 9.8 Billion by 2035.
- PDS0201 for tuberculosis: The global tuberculosis therapeutics market size was valued at USD 2.28 billion in 2024 and is expected to reach USD 3.40 billion by 2032. The U.S. tuberculosis therapeutics market size was valued at USD 0.12 billion in 2024 and is expected to reach USD 0.15 billion by 2032.
- PDS0202, an influenza vaccine candidate: The global influenza vaccine market size was estimated at USD 7.91 billion in 2023 and is projected to reach USD 12.58 billion by 2030. North America led the market with a 53.35% share in 2023.
- PDS0203, a vaccine for the prevention of COVID-19: The COVID-19 vaccine market size globally stood at USD 13.71 billion in 2025 and is projected to contract to USD 8.28 billion by 2030. The global COVID-19 Vaccine Market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for PDS Biotechnology (PDSB)
Over the next 2-3 years, PDS Biotechnology's revenue growth is expected to be driven primarily by the advancement of its clinical pipeline and associated strategic collaborations, rather than immediate product sales, as the company is currently in the clinical development stage with no reported product revenue. Key drivers include:
- Potential Accelerated Approval and Initial Commercialization or Partnership of PDS0101: PDS0101 (Versamune® HPV), the company's lead product candidate, is in a pivotal Phase 3 clinical trial (VERSATILE-003) for HPV16-positive recurrent/metastatic head and neck cancer. PDS Biotechnology is actively pursuing an accelerated approval pathway for PDS0101 by amending the trial protocol to include progression-free survival (PFS) as an interim primary endpoint, which could shorten the timeline to regulatory submission and potential accelerated approval. Positive final results from the preceding VERSATILE-002 Phase 2 trial, which demonstrated a median overall survival of 39.3 months compared to a benchmark of 12-18 months, support this expedited path. If accelerated approval is achieved within the next 2-3 years, it could lead to initial revenue generation through early market access or significant upfront and milestone payments from a commercialization partner.
- Achievement of Milestone Payments from PDS0101 Collaborations: As PDS0101 progresses through its Phase 3 clinical development and towards potential regulatory approval, the company may receive milestone payments from existing or new collaboration partners. The strong clinical data observed in earlier trials and the potential for accelerated approval make PDS0101 an attractive asset for partnerships, which typically include payments tied to development, regulatory, and commercial milestones.
- Advancement and Potential Partnering of PDS01ADC: The company's second lead candidate, PDS01ADC, an IL-12 tumor-targeted immunocytokine, is currently being evaluated in multiple Phase 2 trials across various cancer indications under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Positive clinical data from these ongoing trials, particularly in metastatic castration-resistant prostate cancer, could attract new partnerships or expanded agreements, leading to additional milestone payments or licensing revenues within the specified timeframe.
AI Analysis | Feedback
Share Repurchases
- PDS Biotechnology's Board of Directors approved a share repurchase program of up to $20 million on May 23, 2022, which has been extended annually through May 2025.
- As of June 30, 2025, approximately $10.5 million had been utilized to repurchase 466,374 shares under this program.
- During the first six months of 2025, the company repurchased 40,925 common shares for an aggregate consideration of approximately $1.3 million.
Share Issuance
- PDS Biotechnology filed for a $150 million mixed shelf offering in August 2024, providing authorization for future equity issuances. [cite: Background]
- In February 2025, the company completed a registered direct offering that generated net proceeds of approximately $10.05 million. This offering involved the sale of shares and warrants, with an expected $11 million in immediate funding and a potential additional $11 million from warrant exercises. [cite: 8 from previous search]
- Cash flow statements show net common stock issuances of $22.6 million in 2024, $16.1 million in 2023, $9.9 million in 2022, and $48.5 million in 2021.
Inbound Investments
- In early 2025, PDS Biotechnology entered into a securities purchase agreement that raised $20.0 million, including $22.22 million in principal debentures, primarily used to retire prior debt.
- The February 2025 registered direct offering involved participation from new and existing healthcare-focused institutional investors. [cite: 8 from previous search]
- A November 2025 offering included the sale of shares and pre-funded warrants.
Outbound Investments
- PDS Biotechnology has not made any significant investments in or acquisitions of other companies within the last 3-5 years. [cite: 2 from previous search]
Capital Expenditures
- PDS Biotechnology reported investing cash flow of -$29,000 in 2024.
- Investing cash flow for 2023, 2022, and 2021 was negligible (reported as blank or 0K in the available data).
Trade Ideas
Select ideas related to PDSB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 28.09 |
| Mkt Cap | 11.0 |
| Rev LTM | 1,093 |
| Op Inc LTM | -60 |
| FCF LTM | -61 |
| FCF 3Y Avg | -70 |
| CFO LTM | -60 |
| CFO 3Y Avg | -70 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.3% |
| Rev Chg 3Y Avg | -24.8% |
| Rev Chg Q | 4.7% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | -151.1% |
| Op Mgn 3Y Avg | -115.3% |
| QoQ Delta Op Mgn LTM | -0.9% |
| CFO/Rev LTM | -97.5% |
| CFO/Rev 3Y Avg | -79.2% |
| FCF/Rev LTM | -108.0% |
| FCF/Rev 3Y Avg | -97.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 11.0 |
| P/S | 6.0 |
| P/EBIT | -1.1 |
| P/E | -1.0 |
| P/CFO | -1.1 |
| Total Yield | -19.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -19.7% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.9% |
| 3M Rtn | 16.7% |
| 6M Rtn | 35.4% |
| 12M Rtn | 15.4% |
| 3Y Rtn | -53.4% |
| 1M Excs Rtn | 2.0% |
| 3M Excs Rtn | 19.7% |
| 6M Excs Rtn | 36.0% |
| 12M Excs Rtn | -3.7% |
| 3Y Excs Rtn | -125.1% |
Price Behavior
Price Behavior
| Market Price | $0.65 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/01/2015 | |
| Distance from 52W High | -63.7% | |
| 50 Days | 200 Days | |
| DMA Price | $0.78 | $1.03 |
| DMA Trend | down | down |
| Distance from DMA | -16.6% | -36.8% |
| 3M | 1YR | |
| Volatility | 65.6% | 74.5% |
| Downside Capture | 345.98 | 251.43 |
| Upside Capture | 208.50 | 127.39 |
| Correlation (SPY) | 43.7% | 36.4% |
PDSB Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.96 | 2.27 | 2.50 | 2.18 | 1.30 | 1.85 |
| Up Beta | 2.84 | 3.03 | 1.47 | 1.22 | 0.91 | 1.20 |
| Down Beta | 2.43 | 2.24 | 3.19 | 2.69 | 1.48 | 1.74 |
| Up Capture | 133% | 125% | 218% | 109% | 105% | 505% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 5 | 15 | 25 | 48 | 105 | 330 |
| Down Capture | 446% | 257% | 256% | 239% | 146% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 16 | 26 | 36 | 71 | 133 | 403 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PDSB | |
|---|---|---|---|---|
| PDSB | -49.7% | 74.5% | -0.61 | - |
| Sector ETF (XLV) | 1.6% | 17.6% | -0.06 | 26.2% |
| Equity (SPY) | 17.7% | 18.9% | 0.73 | 36.7% |
| Gold (GLD) | 62.0% | 26.4% | 1.81 | 8.0% |
| Commodities (DBC) | 18.3% | 17.3% | 0.85 | 15.2% |
| Real Estate (VNQ) | 4.2% | 16.1% | 0.08 | 20.1% |
| Bitcoin (BTCUSD) | -12.1% | 44.3% | -0.16 | 25.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PDSB | |
|---|---|---|---|---|
| PDSB | -33.7% | 88.9% | -0.06 | - |
| Sector ETF (XLV) | 6.8% | 14.5% | 0.29 | 25.1% |
| Equity (SPY) | 12.4% | 17.0% | 0.57 | 35.8% |
| Gold (GLD) | 22.6% | 17.3% | 1.07 | 6.8% |
| Commodities (DBC) | 10.7% | 19.0% | 0.45 | 7.3% |
| Real Estate (VNQ) | 4.2% | 18.8% | 0.13 | 24.4% |
| Bitcoin (BTCUSD) | 5.0% | 56.7% | 0.31 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PDSB | |
|---|---|---|---|---|
| PDSB | -42.4% | 99.1% | 0.01 | - |
| Sector ETF (XLV) | 10.0% | 16.5% | 0.49 | 18.4% |
| Equity (SPY) | 14.6% | 17.9% | 0.70 | 23.6% |
| Gold (GLD) | 14.1% | 15.7% | 0.75 | 5.7% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 9.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 14.3% |
| Bitcoin (BTCUSD) | 67.9% | 66.8% | 1.07 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -9.1% | -25.6% | -8.1% |
| 8/13/2025 | -5.7% | -4.9% | -4.1% |
| 3/27/2025 | 0.8% | -6.9% | 0.8% |
| 11/14/2024 | -18.3% | -26.5% | -33.2% |
| 8/13/2024 | 0.0% | 15.4% | 1.6% |
| 3/27/2024 | -14.1% | -17.9% | -27.2% |
| 11/14/2023 | 18.6% | 20.1% | -0.7% |
| 8/14/2023 | 10.3% | 5.3% | 3.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 10 |
| # Negative | 8 | 9 | 8 |
| Median Positive | 2.9% | 6.7% | 3.6% |
| Median Negative | -6.2% | -9.2% | -18.7% |
| Max Positive | 26.1% | 54.5% | 58.4% |
| Max Negative | -18.3% | -26.5% | -33.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.